29 October 2018 - - German health care company Fresenius Kabi has launched Arsenic Trioxide Injection in a 10 mg per 10 mL vial presentation in the U.S. market, with immediate availability, the company said.

The product is the first-to-market generic of Trisenox indicated for relapsed or refractory acute promyelocytic leukemia.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

The company is a leading developer, manufacturer and provider of injected and infused medicines in the United States with expertise in producing affordable generic alternatives to more expensive brand-name drugs.

Arsenic Trioxide Injection is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterised by the presence of the translocation or PML/RAR-alpha gene expression.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

The company's products and services are used to help care for critically and chronically ill patients. The company's US headquarters is in Lake Zurich, Illinois. The company's global headquarters is in Bad Homburg, Germany.

Trisenox is a registered trademark of Teva Pharmaceutical Industries Ltd.